Oxidized low-density lipoprotein prevented hepatitis C virus from entering liver cells and predicted interferon response among patients with chronic H... More »
Individuals with hepatitis C infection are three times more likely to develop cirrhosis than are those who are hepatitis C negative, and fibrosis prog... More »
Immunity against the hepatitis C virus can be induced by cultured primary human liver sinusoidal endothelial cells, according to a study published in ... More »
BOSTON – Terlipressin proved noninferior to noradrenaline as a vasopressor for patients with cirrhosis and septic shock in an open-label study that randomized 84 patients.
Terlipressin also seemed...
Administration of a novel fatty acid–bile acid conjugate safely and significantly reduced liver fat content in patients with nonalcoholic fatty liver disease in a phase II trial.
Administration of...
Two interferon-free combination therapies yielded sustained virologic responses of 96%-100% in an international, open-label, phase III, randomized trial involving 186 patients with refractory...
Veterans with genotype 3 hepatitis C virus infection were 31% more likely to develop cirrhosis and 80% more likely to develop liver cancer than were patients with genotype 1 infection, reported the...
Nucleoside analogues are effective at preventing hepatocellular carcinoma in hepatitis B, but all are not equal when it comes to overall mortality and liver transplant, according to two new studies...
CHICAGO – The oral drug duo of sofosbuvir and ribavirin produced good cure rates in a study of 419 patients with hepatitis C genotype 2 or 3.
Dr. Bruce R. Bacon, who was not involved in the study,...
CHICAGO – The oral drug duo of sofosbuvir and ribavirin produced good cure rates in a study of 419 patients with hepatitis C genotype 2 or 3.
Dr. Bruce R. Bacon, who was not involved in the study,...